Skip to main content

View full-text article in PMC

. 2023 Oct 16;39(4):529–539. doi: 10.1007/s11606-023-08443-6

Table 2.

Changes in Clinical Measurements of Study Participants from Baseline to Study Endpoint

	Intervention Group					Control Group
	n	Baseline, mean (SD)	Endpoint, mean (SD)	Change	p-value	n	Baseline, mean (SD)	Endpoint, mean (SD)	Change	p-value	Intervention Effect—Adjusted^a	p-value
HbA1c, %	28	7.1 (1.1)	6.7 (0.8)	-0.4 (-0.8, -0.1)	0.014	19	7.1 (1.0)	6.9 (0.9)	-0.2 (-0.7, 0.3)	0.382	-0.2 (-0.7, 0.3)	0.493
Weight, lbs	92	157.4 (22.7)	152.6 (26.0)	-4.8 (-8.2, -1.4)	0.006	91	156.7 (26.8)	157.3 (27.5)	0.5 (-1.3, 2.4)	0.565	-5.2 (-9.0, -1.4)	0.007
BMI, kg/m²	92	27.8 (4.3)	26.8 (4.5)	-0.9 (-1.6, -0.2)	0.012	91	26.6 (4.3)	26.7 (4.4)	0.1 (-0.2, 0.4)	0.547	-0.1 (-1.7, -0.2)	0.012
SBP, mmHg	92	139.8 (16.4)	126.1 (11.3)	-13.6 (-17.1, -10.2)	< 0.001	91	139.0 (16.3)	132.5 (12.4)	-6.5 (-10.3, -2.7)	0.001	-6.7 (-11.6, -1.6)	0.009
DBP, mmHg	92	85.0 (9.5)	76.8 (9.2)	-8.2 (-10.3, -6.0)	< 0.001	91	84.3 (9.1)	81.0 (7.4)	-3.4 (-5.3, -1.4)	< 0.001	-4.7 (-7.5, -1.8)	0.001
BP Control^b, n (%)	92	6 (6.5)	37 (40.2)	33.7 (22.5, 44.9)	< 0.001	91	7 (7.7)	22 (24.2)	16.5 (6.2, 26.8)	0.003	1.8 (1.0, 3.2)	0.055

^aAdjusted for age and gender

^b < 130/80 mmHg